The First Medical Device Acquisition in China for the Johnson & Johnson Family of Companies is Guangzho Bioseal Who’s Biologic Product Complements J&J’s Existing Haemostat Portfolio.
Haemostasis
Fibrocaps™ Haemostat Study Shows Promising Reduction In Time To Haemostasis
Dutch Haemostasis and Regenerative Medicine company ProFibrix B.V., has announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general surgery resulted in a highly statistically significant reduction in mean time to haemostasis and incidence of haemostasis at 3, 5 and 10 minutes, as compared to active control.